EGFR and non-small cell lung carcinoma: In Taiwan, we also demonstrated that advanced EGFR-mutant NSCLC patients being treated with sequential osimertinib experienced an OS of more than 60 months if T790M mutation was noted after gaining resistance to first- and second-generation EGFR-TKIs [14].